Literature DB >> 23352221

Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy.

Wei Liao1, Jian-Xin Lin, Warren J Leonard.   

Abstract

Interleukin-2 (IL-2) is a pleiotropic cytokine produced after antigen activation that plays pivotal roles in the immune response. Discovered as a T cell growth factor, IL-2 additionally promotes CD8(+) T cell and natural killer cell cytolytic activity and modulates T cell differentiation programs in response to antigen, promoting naïve CD4(+) T cell differentiation into T helper 1 (Th1) and T helper 2 (Th2) cells while inhibiting T helper 17 (Th17) and T follicular helper (Tfh) cell differentiation. Moreover, IL-2 is essential for the development and maintenance of T regulatory cells and for activation-induced cell death, thereby mediating tolerance and limiting inappropriate immune reactions. In this review, we focus on the molecular mechanisms and complex cellular actions of IL-2, its cooperative and opposing effects with other cytokines, and how both promoting and blocking the actions of IL-2 are being utilized in clinical medicine.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23352221      PMCID: PMC3610532          DOI: 10.1016/j.immuni.2013.01.004

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  155 in total

1.  IL-9 production of naive CD4+ T cells depends on IL-2, is synergistically enhanced by a combination of TGF-beta and IL-4, and is inhibited by IFN-gamma.

Authors:  E Schmitt; T Germann; S Goedert; P Hoehn; C Huels; S Koelsch; R Kühn; W Müller; N Palm; E Rüde
Journal:  J Immunol       Date:  1994-11-01       Impact factor: 5.422

2.  Heterodimerization of the IL-2 receptor beta- and gamma-chain cytoplasmic domains is required for signalling.

Authors:  Y Nakamura; S M Russell; S A Mess; M Friedmann; M Erdos; C Francois; Y Jacques; S Adelstein; W J Leonard
Journal:  Nature       Date:  1994-05-26       Impact factor: 49.962

3.  Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor.

Authors:  V A Boussiotis; D L Barber; T Nakarai; G J Freeman; J G Gribben; G M Bernstein; A D D'Andrea; J Ritz; L M Nadler
Journal:  Science       Date:  1994-11-11       Impact factor: 47.728

4.  Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits.

Authors:  T Miyazaki; A Kawahara; H Fujii; Y Nakagawa; Y Minami; Z J Liu; I Oishi; O Silvennoinen; B A Witthuhn; J N Ihle
Journal:  Science       Date:  1994-11-11       Impact factor: 47.728

5.  Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID.

Authors:  S M Russell; J A Johnston; M Noguchi; M Kawamura; C M Bacon; M Friedmann; M Berg; D W McVicar; B A Witthuhn; O Silvennoinen
Journal:  Science       Date:  1994-11-11       Impact factor: 47.728

6.  Cytoplasmic domains of the interleukin-2 receptor beta and gamma chains mediate the signal for T-cell proliferation.

Authors:  B H Nelson; J D Lord; P D Greenberg
Journal:  Nature       Date:  1994-05-26       Impact factor: 49.962

7.  CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition.

Authors:  Michael S von Bergwelt-Baildon; Alexey Popov; Tomo Saric; Jens Chemnitz; Sabine Classen; Marc S Stoffel; Francesca Fiore; Udo Roth; Marc Beyer; Svenja Debey; Claudia Wickenhauser; Franz-Georg Hanisch; Joachim L Schultze
Journal:  Blood       Date:  2006-03-07       Impact factor: 22.113

8.  Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells.

Authors:  Matthew A Williams; Aaron J Tyznik; Michael J Bevan
Journal:  Nature       Date:  2006-06-15       Impact factor: 49.962

9.  T helper type 1-specific Brg1 recruitment and remodeling of nucleosomes positioned at the IFN-gamma promoter are Stat4 dependent.

Authors:  Fuping Zhang; Mark Boothby
Journal:  J Exp Med       Date:  2006-05-22       Impact factor: 14.307

10.  Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15.

Authors:  J G Giri; M Ahdieh; J Eisenman; K Shanebeck; K Grabstein; S Kumaki; A Namen; L S Park; D Cosman; D Anderson
Journal:  EMBO J       Date:  1994-06-15       Impact factor: 11.598

View more
  358 in total

Review 1.  Single-cell mass cytometry for analysis of immune system functional states.

Authors:  Zach B Bjornson; Garry P Nolan; Wendy J Fantl
Journal:  Curr Opin Immunol       Date:  2013-08-31       Impact factor: 7.486

Review 2.  Modulation of autoimmune rheumatic diseases by oestrogen and progesterone.

Authors:  Grant C Hughes; Divaker Choubey
Journal:  Nat Rev Rheumatol       Date:  2014-08-26       Impact factor: 20.543

Review 3.  Regulation of human helper T cell subset differentiation by cytokines.

Authors:  Nathalie Schmitt; Hideki Ueno
Journal:  Curr Opin Immunol       Date:  2015-04-11       Impact factor: 7.486

4.  Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2.

Authors:  Eric F Zhu; Shuning A Gai; Cary F Opel; Byron H Kwan; Rishi Surana; Martin C Mihm; Monique J Kauke; Kelly D Moynihan; Alessandro Angelini; Robert T Williams; Matthias T Stephan; Jacob S Kim; Michael B Yaffe; Darrell J Irvine; Louis M Weiner; Glenn Dranoff; K Dane Wittrup
Journal:  Cancer Cell       Date:  2015-04-13       Impact factor: 31.743

Review 5.  Human cell-based artificial antigen-presenting cells for cancer immunotherapy.

Authors:  Marcus O Butler; Naoto Hirano
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

6.  Treg sensitivity to FasL and relative IL-2 deprivation drive idiopathic aplastic anemia immune dysfunction.

Authors:  Shok Ping Lim; Benedetta Costantini; Syed A Mian; Pilar Perez Abellan; Shreyans Gandhi; Marc Martinez Llordella; Juan Jose Lozano; Rita Antunes Dos Reis; Giovanni A M Povoleri; Thanos P Mourikis; Ander Abarrategi; Linda Ariza-McNaughton; Susanne Heck; Jonathan M Irish; Giovanna Lombardi; Judith C W Marsh; Dominique Bonnet; Shahram Kordasti; Ghulam J Mufti
Journal:  Blood       Date:  2020-08-13       Impact factor: 22.113

7.  A good manufacturing practice method to ex vivo expand natural killer cells for clinical use.

Authors:  Giovanni F Torelli; Carmela Rozera; Laura Santodonato; Nadia Peragine; Giuseppina D'agostino; Enrica Montefiore; Maria R Napolitano; Domenica M Monque; Davide Carlei; Paola Mariglia; Simona Pauselli; Maria Gozzer; Mahnaz Shafii Bafti; Gabriella Girelli; Anna Guarini; Filippo Belardelli; Robin Foà
Journal:  Blood Transfus       Date:  2015-01-30       Impact factor: 3.443

Review 8.  Beyond regulatory T cells: the potential role for IL-2 to deplete T-follicular helper cells and treat autoimmune diseases.

Authors:  André Ballesteros-Tato
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

9.  Knockdown of T-bet expression in Mart-127-35 -specific T-cell-receptor-engineered human CD4(+)  CD25(-) and CD8(+) T cells attenuates effector function.

Authors:  Sidharth S Jha; Nitya G Chakraborty; Prashant Singh; Bijay Mukherji; David I Dorsky
Journal:  Immunology       Date:  2015-05       Impact factor: 7.397

10.  Opposing actions of IL-2 and IL-21 on Th9 differentiation correlate with their differential regulation of BCL6 expression.

Authors:  Wei Liao; Rosanne Spolski; Peng Li; Ning Du; Erin E West; Min Ren; Suman Mitra; Warren J Leonard
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-18       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.